Is Becton Dickinson and Company (BDX) overvalued? · P/E 34, rev $21.84B
Becton Dickinson and Company (BDX) is a medical instruments & supplies company listed on US.
This page asks whether Becton Dickinson and Company (BDX) looks expensive on cached numbers — not a short thesis.
Latest reported BDX revenue for 2025-09-30 was $21.84B. Net income was $1.68B. Revenue was up 8.2% from 2024-09-30 to 2025-09-30. BDX currently screens at market cap $50.30B and trailing P/E 33.9.
BDX currently screens at market cap $50.30B and trailing P/E 33.9. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next BDX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the BDX stock page for the full model, not this heading.
Not investment advice.